InvestorsHub Logo
Followers 17
Posts 969
Boards Moderated 0
Alias Born 03/07/2002

Re: None

Sunday, 09/20/2020 1:59:12 PM

Sunday, September 20, 2020 1:59:12 PM

Post# of 693267
Hmmmm, a new platform?
Where have I heard that?

The results boost Gilead’s hopes of finding a “platform in a product.” While some analysts questioned whether the deal was worth the cost, SVB Leerink’s Geoffrey Porges said Gilead anticipated the ESMO data would “alter (positively) investor’s perceptions of the drug and would have created significant upwards pressure on the company’s value (thus justifying their lofty premium).”

https://endpts.com/esmo20-trodelvy-data-shows-big-gilead-buyout-may-have-been-worth-the-premium/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News